Table 1 Characteristics of the eligible studies included in the systematic assessment
Author and Year | Study design | Area | Study arms | Number of patients | mPFS(m) | mOS(m) | ORR(%) | DCR(%) |
|---|---|---|---|---|---|---|---|---|
Higuchi K 2014 [10] | phase III clinical trial | Japan | irinotecan+cisplatin | 64 | 3.8 | 10.7 | 22.0 | 75.0 |
irinotecan | 63 | 2.8 | 10.1 | 16.0 | 54.0 | |||
Nishikawa K 2015 [11] | phase III clinical trial | Japan | irinotecan+cisplatin | 82 | 4.6 | 13.9 | 17.0 | 69.0 |
irinotecan | 81 | 4.1 | 12.7 | 16.0 | 65.0 | |||
Oba M 2011 [17] | retrospective study | Japan | irinotecan+cisplatin | 42 | 2.7 | 9.8 | 20.0 | 54.3 |
irinotecan | 92 | 2.6 | 8 | 8.1 | 54.1 | |||
Satoh T 2015 [12] | phase II clinical trial | Japan and Korea | irinotecan+nimotuzumab | 40 | 2.4 | 8.3 | 18.4 | 47.4 |
irinotecan | 43 | 2.8 | 7.7 | 10.3 | 46.2 | |||
Sym SJ 2013 [13] | phase II clinical trial | Korea | irinotecan+ 5-fluorouracil | 30 | 3 | 6.7 | 20.0 | 56.7 |
irinotecan | 29 | 2.2 | 5.8 | 17.2 | 48.2 | |||
Tanabe K 2015 [14] | phase II/III clinical trial | Japan | irinotecan+S1 | 145 | 3.8 | 8.8 | 9.0 | 48.0 |
irinotecan | 148 | 3.4 | 9.5 | 9.0 | 53.0 | |||
Ueda A 2013 [16] | retrospective study | Japan | irinotecan+mitomycin C | 22 | 3.9 | 9.6 | 19.0 | 86.0 |
irinotecan | 24 | 3.7 | 8.7 | 10.0 | 62.0 |